Related Experiment Video
Updated: May 13, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
What is the future for drug development in atherosclerosis and dyslipidaemia?
1291 Knightsfield, Welwyn Garden City, Herts AL8 7NH, UK +44 1707 330022 ; +44 1707 330022 ; keith@suckling291.freeserve.co.uk.
Abstract:
Major companies have recently announced a reduction or termination of their work in cardiovascular disease, specifically atherosclerosis and dyslipidaemia. This editorial considers the background to these developments, relating it to the continuing development of the lipoprotein-associated phospholipase A2 inhibitor darapladib and the potential for the field in the future.
Related Concept Videos
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis I: Introduction
Atherosclerosis IV: Nursing Management
Coronary Artery Disease I: Introduction